Latest Content

Amanda Nanasy, OD, described how her own concussion shaped her approach to athletes and why she ties every vision evaluation back to the demands of their sport.

Zachary Keaney, CPOA, discusses the lens care steps patients skip most often and why early diagnosis of lens-related keratitis is critical.

This week's top stories include breaking FDA approvals, insights on AI-assisted front desk management, and more.

Open-access OCTA tools showed similar reliability, but different vessel density values in glaucoma; researchers advise using one tool consistently.

Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier time points.

CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.

Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.

Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.

Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.

From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.

Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for managing near vision loss.

Enspryng is the first subcutaneous, at-home treatment option for TED and the first IL-6 receptor inhibitor approved for this indication.

Susan Gromacki, OD, MS, FAAO, FSLS, details one of her AAOpt 2026 sessions, titled "Advances in Contact Lens Care for the New Contact Lens Technologies."